CN109200243A - A kind of blood-fat reducing composition, preparation and the preparation method and application thereof - Google Patents
A kind of blood-fat reducing composition, preparation and the preparation method and application thereof Download PDFInfo
- Publication number
- CN109200243A CN109200243A CN201811159872.7A CN201811159872A CN109200243A CN 109200243 A CN109200243 A CN 109200243A CN 201811159872 A CN201811159872 A CN 201811159872A CN 109200243 A CN109200243 A CN 109200243A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood
- preparation
- auxiliary material
- major ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 210000004369 blood Anatomy 0.000 claims abstract description 72
- 239000008280 blood Substances 0.000 claims abstract description 72
- 239000000463 material Substances 0.000 claims abstract description 48
- 239000004615 ingredient Substances 0.000 claims abstract description 41
- 150000002632 lipids Chemical class 0.000 claims abstract description 41
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 12
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 12
- 244000302512 Momordica charantia Species 0.000 claims abstract description 11
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 11
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 11
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 11
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 11
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 11
- 229930182490 saponin Natural products 0.000 claims abstract description 11
- 150000007949 saponins Chemical class 0.000 claims abstract description 11
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims abstract description 10
- 229960001661 ursodiol Drugs 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 125000005629 sialic acid group Chemical group 0.000 claims abstract description 9
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 8
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 17
- 210000000582 semen Anatomy 0.000 claims description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- 235000019441 ethanol Nutrition 0.000 claims description 12
- 239000000341 volatile oil Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 240000005528 Arctium lappa Species 0.000 claims description 8
- 235000003130 Arctium lappa Nutrition 0.000 claims description 8
- 241000717739 Boswellia sacra Species 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 239000004863 Frankincense Substances 0.000 claims description 8
- 241000253121 Inula britannica Species 0.000 claims description 8
- 241000951473 Schizonepeta Species 0.000 claims description 8
- 210000001367 artery Anatomy 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 210000003462 vein Anatomy 0.000 claims description 8
- 240000001592 Amaranthus caudatus Species 0.000 claims description 7
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 7
- 244000163122 Curcuma domestica Species 0.000 claims description 7
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 7
- 241000218231 Moraceae Species 0.000 claims description 7
- 235000008708 Morus alba Nutrition 0.000 claims description 7
- 241000237636 Pheretima Species 0.000 claims description 7
- 241000270295 Serpentes Species 0.000 claims description 7
- 241000320380 Silybum Species 0.000 claims description 7
- 235000010841 Silybum marianum Nutrition 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- 235000012735 amaranth Nutrition 0.000 claims description 7
- 239000004178 amaranth Substances 0.000 claims description 7
- 235000003373 curcuma longa Nutrition 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- 235000013976 turmeric Nutrition 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 6
- 239000000347 magnesium hydroxide Substances 0.000 claims description 6
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- -1 sorbitan fatty acid ester Chemical class 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 229910021485 fumed silica Inorganic materials 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000004513 sizing Methods 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 229940107200 chondroitin sulfates Drugs 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002107 myocardial effect Effects 0.000 abstract description 2
- 230000036284 oxygen consumption Effects 0.000 abstract description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 22
- 229950006238 nadide Drugs 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 241000208340 Araliaceae Species 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000132521 Erigeron Species 0.000 description 7
- 108010024137 Nicotinamide-Nucleotide Adenylyltransferase Proteins 0.000 description 7
- 102000015597 Nicotinamide-nucleotide adenylyltransferase Human genes 0.000 description 7
- 229940089161 ginsenoside Drugs 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910017435 S2 In Inorganic materials 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of blood-fat reducing compositions, including major ingredient and auxiliary material, major ingredient in parts by weight, including 2-10 parts of NADH, 1-8 parts of Herba Epimedii, PPD, 1-6 parts of ginseng saponin Rh 2s of 2-8 parts of ginsenosides, 2-5 parts of grape seed extracts, 1-5 parts of chondroitin sulfates, 1-6 parts of ursodesoxycholic acid, 1-4 parts of Sialic acids, 1-7 parts of s- Ademetionines, 1-8 parts of γ-aminobutyric acids；The balsam pear seed extract of 1-10 parts by weight.It acts synergistically between composition each component, the effect for having good blood fat reducing function, and having expansion blood vessel, improving blood circulation, increase coronary flow, reducing myocardial oxygen consumption can integrate and have the function that aided blood pressure-lowering reducing blood lipid.Also disclose the application of the preparation containing the composition, the preparation method of preparation and the composition, the preparation method of preparation is simple and convenient, mild condition, is suitable for industrialized mass production, composition can be used for preparing blood lipid-lowering medicine or food.
Description
Technical field
The invention belongs to medical supplies technical field, a kind of blood-fat reducing composition, preparation and its preparation are related in particular to
Method and application.
Background technique
Blood lipid is the general name of contained lipid in blood, mainly includes cholesterol (TC), triglycerides (TG) phosphatide and fat
Acid etc., as national life level improves, dietary structure is improper to lead to cholesterol in blood of human body, triglyceride, low density lipoprotein
Protein cholesterol (LDL-C) obviously increases, and high-density lipoprotein cholesterol (HDL-C) reduces.With human diseases structure
Change, the formidable opponent of human health is increasingly becoming by the disease that hyperlipidemia causes.
Hyperlipidemia is " rich people's disease " derived from one is modern society, is the source of many diseases, and it is " heavy to be referred to as
Silent killer ", the damage to body be concealment, gradually, progressive and systemic.Its direct damage is to accelerate whole body dynamic
Pulse atherosclerosis, hyperlipemia cause atherosclerosis to be the arch-criminal of cardiovascular and cerebrovascular disease.Hyperlipemia can also result in
Fatty liver, cirrhosis, cholelithiasis, pancreatitis, fundus hemorrhage, blindness, peripheral vascular disease, limping, hyperuricemia etc..
Living standards of the people significantly improve the consumption idea of people in recent years, concept of health is varied widely, for rule
The various adverse effects of unhealthy bring are kept away, people is made increasingly to pay attention to the use of nutrient and healthcare products.
Currently, Western medicine is used mostly at present for reducing blood lipid is domestic, but Western medicine is taken for a long time to actual bodily harm very
Greatly, side effect is strong, and long-time service dependence is big, bears kidney strong.Currently, also there is least a portion of Chinese medicine composition gradually to emerge in large numbers
Out, have a certain curative effect to reducing blood lipid, but big multicomponent effect is uncertain, effective component is also inaccurate, side effect also without
Cross investigation.Therefore it is determining to find a kind of effective component, the effective composition and its preparation for promoting reducing blood lipid, is this field
Thing very urgent at present.
Summary of the invention
For this purpose, the present invention exactly will solve above-mentioned technical problem, thus propose a kind of composition that can reduce blood lipids index,
The application of the preparation method and composition of preparation and preparation.
In order to solve the above technical problems, the technical solution of the present invention is as follows:
The present invention provides a kind of blood-fat reducing composition, including major ingredient and auxiliary material, the major ingredient in parts by weight, including 2-10
Part NADH, 1-8 parts of Herba Epimedii, PPD, 1-6 parts of ginseng saponin Rh 2s of 2-8 parts of ginsenosides, 2-5 parts of grape seed extracts, 1-5 parts
Chondroitin sulfate, 1-6 part ursodesoxycholic acid, 1-4 parts of Sialic acids, 1-7 parts of s- Ademetionines, 1-8 parts of γ-aminobutyric acids, 1-
10 parts of balsam pear seed extracts.
Preferably, the auxiliary material is in parts by weight, including at least eight kinds of of following component: 2-5 parts of Radix Rehmanniae, purple pone
1-3 parts, 2-4 parts of cassia seed, 1-4 parts of radix aconiti agrestis snake, 1-3 parts of Rhizoma Chuanxiong, 0.5-2 parts of pheretima, 0.3-3 parts of hoveniae semoveniae semen, schizonepeta carbon 2-6
Part, aobvious 4-6 parts of arteries and veins Inula britannica chinensis, 2-4 parts of great burdock achene, 1-3 parts of olibanum, 1-2 parts of fleabane flower, 0.5-3 parts of dried orange peel, 2-6 parts of milk thistle,
Pierce amaranth 2-4 parts, 1-3 parts of semen astragali complanati, 0.5-3 parts of mulberries, 3-5 parts of turmeric.
Preferably, the auxiliary material is in parts by weight, at least three kinds: the Nipagin complex esters 0.5- also comprised the following components
2 parts, 1-2 parts of fumaric acid, 1-3 parts of xylitol, 3-6 parts of microcrystalline cellulose, 1-5 parts of sorbitan fatty acid ester, magnesium stearate
1-3 parts, 2-6 parts of croscarmellose sodium, 2-5 parts of magnesium hydroxide, 1-10 parts of pregelatinated shallow lake, 1-5 parts of calcium sulfate, gas phase two
3-6 parts of silica, 1-4 parts of lactose.
The present invention also provides a kind of blood fat reducing preparation, the preparation includes combination as described in any one of claims 1-3
Object.
The present invention also provides a kind of methods for preparing the preparation comprising following steps:
S1, major ingredient and auxiliary material are crossed into 30-80 mesh respectively, keep grain graininess uniform；
S2, proportionally major ingredient, auxiliary material and water stirred at 25-40 DEG C；
S3,1h is stirred to get reducing blood lipid aqua after the obtained mixture of step S2 is warming up to 50 DEG C.
The present invention also provides a kind of methods for preparing the preparation comprising following steps:
S1, dry major ingredient and auxiliary material each component are crossed into 60 meshes, and weighing mixing in proportion；
Whole grain and compressing tablet process are carried out after S2, the mixture drying for obtaining step S1, obtains reducing blood lipid tablet.
The present invention also provides a kind of methods for preparing the preparation comprising following steps:
S1, major ingredient and auxiliary material each component are crossed into 60 meshes, and weighing mixing in proportion；
S2, the obtained mixture of step S1 is filled in flexible glue utricule, and passes through pelleting, sizing drying, washes ball, dries in the air
Ball picks up the step of ball, is reduced blood lipid soft capsule.
The present invention also provides a kind of methods for preparing the preparation comprising following steps:
S1, auxiliary material component is crushed as particle, addition ethyl alcohol and heating and refluxing extraction 2h, the additive amount of ethyl alcohol into particle
It is 5 times of component particles quality, first time filtration treatment obtains the dregs of a decoction and medical fluid, and the ethyl alcohol that the dregs of a decoction are measured with 3 times is heated to reflux
1h is extracted, second of filtration treatment mixes the medical fluid being obtained by filtration for the first time, for the second time, and is concentrated under reduced pressure and is made relatively close
Degree is that the thick paste of 1.35-1.4 is spare；
S2, the water that the obtained thick paste of step S1 is added to 7 times of amounts, heating and refluxing extraction 4h obtain volatile oil, the dregs of a decoction and medical fluid
Mixture, point take the volatile oil, and the dregs of a decoction and medical filtration are separated, obtain supernatant and the solid dregs of a decoction；
S3, major ingredient is mixed with the obtained volatile oil of step S2 and the dregs of a decoction, adds the water boiling and extraction 2h of 18 times of amounts, filters
To filtrate and filter residue, filtrate is centrifugated, obtains the first supernatant；By filter residue plus 12 times of water boiling and extraction 1h measured, filtering
Filtrate and filter residue are obtained, filtrate is centrifugated, obtains the second supernatant；By the first supernatant, the second supernatant and step S2
In supernatant mixing, be concentrated under reduced pressure be made relative density be 1.35-1.4 thick paste it is spare；
S4, dextrin, superfine silica gel powder are mixed and is stirred together for uniformly with thick paste made from step S3, the mixture that will be obtained
After drying and crushing, dextrin is added, is sieved, mixes and is packed into capsule shells after spraying into the volatile oil that step S2 is obtained, obtains drop blood
Rouge capsule.
Preferably, the volumetric concentration of the ethyl alcohol is 70%.
The present invention also provides application of the composition described in one kind in blood lipid-lowering medicine or food.
The above technical solution of the present invention has the following advantages over the prior art:
(1) blood-fat reducing composition of the present invention, including major ingredient and auxiliary material, the major ingredient in parts by weight, including 2-
10 parts of NADH, 1-8 parts of Herba Epimedii, PPD, 1-6 parts of ginseng saponin Rh 2s of 2-8 parts of ginsenosides, 2-5 parts of grape seed extracts, 1-5
Part chondroitin sulfate, 1-6 parts of ursodesoxycholic acid, 1-4 parts of Sialic acids, 1-7 parts of s- Ademetionines, 1-8 parts of γ-aminobutyric acids；
The balsam pear seed extract of 1-10 parts by weight.It acts synergistically between the composition each component, there is good blood fat reducing function, and
Tool expansion blood vessel, the effect for improving blood circulation, increasing coronary flow, reduction myocardial oxygen consumption, can integrate and reach auxiliary drop blood
The effect of pressure drop blood lipid.The composition can obviously reduce blood lipid, to hypercholesterolemia, hypertriglyceridemia and mixed type
Hyperlipidemia has apparent therapeutic effect, and clinical observation, therapeutic effect is up to 98%.The composition has been put forward for the first time will
NADH and grape seed extract, ginsenoside PPD, ginseng saponin Rh 2 etc. are clear effectively at subassembly, are added specific other
Component significantly improves the effect of composition reducing blood lipid, and synergistic effect is played between each component.
Wherein, the NADH (Nicotinamide adenine dinucleotide) is two nucleoside of nicotinamide adenine
The reduction-state of acid, for the citrate cycle in glycolysis and cellular respiration.NADH is present in each living cells of human body, it
React with oxygen, generate energy, thousands of kinds of physiological metabolism reactions intracorporal to people all play a crucial role.People
In body NADH content number it is closely bound up with many diseases, NADH can activate DNA repair enzyme (PARP), rapidly repair damage
DNA, prevent it from evolving into cancer.Moreover, NADH or superpower antioxidant can remove interior free yl, prevent cancer
Process.Balsam pear seed extract has reduction blood lipid level, counteracting blood lipid due to caused by cholesterol absorption is excessive raised
Effect.
(2) blood-fat reducing composition of the present invention, the auxiliary material in parts by weight, including at least eight kinds of of following component:
2-5 parts of Radix Rehmanniae, purple 1-3 parts of pone, 2-4 parts of cassia seed, 1-4 parts of radix aconiti agrestis snake, 1-3 parts of Rhizoma Chuanxiong, 0.5-2 parts of pheretima, hoveniae semoveniae semen
0.3-3 parts, 2-6 parts of schizonepeta carbon, aobvious 4-6 parts of arteries and veins Inula britannica chinensis, 2-4 parts of great burdock achene, 1-3 parts of olibanum, 1-2 parts of fleabane flower, dried orange peel
0.5-3 parts, 2-6 parts of milk thistle, thorn amaranth 2-4 parts, 1-3 parts of semen astragali complanati, 0.5-3 parts of mulberries, 3-5 parts of turmeric.In NADH, ginseng soap
On the basis of the ingredients such as glycosides, grape seed extract, above-mentioned traditional Chinese medicinal components are additionally used, traditional Chinese and western medicine theory combines, and plays aobvious
Write the effect for reducing blood lipid.
(3) blood-fat reducing composition of the present invention, the auxiliary material in parts by weight, at least three including following component
Kind: 0.5-2 parts of Nipagin complex esters, 2-4 parts of phosphate, 1-3 parts of xylitol, 3-6 parts of microcrystalline cellulose, lose 1-2 parts of fumaric acid
It is 1-5 parts of water Span, 1-3 parts of magnesium stearate, 2-6 parts of croscarmellose sodium, 2-5 parts of magnesium hydroxide, pre-
1-10 parts of gelatinization shallow lake, 1-5 parts of calcium sulfate, 3-6 parts of fumed silica, 1-4 parts of lactose.The introducing of above-mentioned auxiliary material can be improved other
Major ingredient medicinal material is to the facilitation of reducing blood lipid, and main and supplementary materials synergistic effect, component nonhazardous is highly-safe, is that one kind can be entirely square
Composition of the position for a kind of reduction blood lipids index of multiple links.
(4) preparation method of blood fat reducing preparation of the present invention, method and step is simple, working condition is mild, is suitable for
Industrialized mass production.
Specific embodiment
In order to make the content of the present invention more clearly understood, below according to specific embodiments of the present invention to this hair
It is bright to be described in further detail.
Embodiment 1
The present embodiment provides a kind of blood-fat reducing compositions comprising major ingredient and auxiliary material, wherein major ingredient in parts by weight, including
2 parts of NADH, 1 part of Herba Epimedii, 2 parts of ginsenoside PPD, 1 part of ginseng saponin Rh 2,2 parts of grape seed extracts, 1 part of chondroitin sulfate
The balsampear seed extraction of element, 1 part of ursodesoxycholic acid, 1 part of Sialic acid, 1 part of s- Ademetionine, 1 part of γ-aminobutyric acid, 1 parts by weight
Object.
In parts by weight, the auxiliary material includes 2 parts of Radix Rehmanniae, purple 1 part of pone, 2 parts of cassia seed, 1 part of radix aconiti agrestis snake, Rhizoma Chuanxiong 1
Part, 0.5 part of pheretima, 0.3 part of hoveniae semoveniae semen, 2 parts of schizonepeta carbon, 0.5 part of Nipagin complex esters, 1 part of fumaric acid, 1 part of xylitol, crystallite
3 parts of cellulose.
The present embodiment also provides a kind of blood fat reducing preparation, and the blood fat reducing preparation includes above-mentioned composition, the reducing blood lipid
Preparation is prepared with the following method:
S1, major ingredient and auxiliary material are crossed into 30 meshes respectively, keep grain graininess uniform；
S2, proportionally major ingredient, auxiliary material and water stirred at 25 DEG C；
S3,1h is stirred after the obtained mixture of step S2 is warming up to 50 DEG C to get the aqua of reduction blood lipid is promoted.
The NADH is prepared with the following method:
1, the crude extract or its pure enzyme of nicotinamide-nucleotide adenylyltransferase are extracted.
2, the crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase.
3, it is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, with nicotinamide nucleotide and atriphos two
Sodium (ATP) is that substrate prepares nicotinamide adenine dinucleotide.
Specific step is as follows:
By the plasmid pRSET bmj transformed competence colibacillus bacterial cell of niacinamide-containing nucleosides adenylyl transferase gene
E.coliHB101 is cultivated 24 hours at upper 37 DEG C of Luriabroth (LB) plate (kanamycins containing 100mg/L).Inoculation is single
Be cloned in 5 milliliters of LB liquid mediums (kanamycins containing 100mg/L) and in 30 DEG C culture 20-24 hours.Bacterium is collected by centrifugation
Body, and be suspended in 1 milliliter of 100mM Tris hydrochloride buffer (pH7.5).Then ultrasonic treatment bacterial cell is used.Centrifugation
(10 DEG C, 17800g, 10 minutes) and supernatant is collected, as thick leach protein (or crude extract).The nicotinamide riboside gland of recombination
Glycosides acyltransferase thick leach protein is heat-treated 10 minutes through 70 DEG C, is centrifuged (10 DEG C, 17800g, 10 minutes) and is collected supernatant, i.e.,
For partially purified albumen.
Nicotinamide-nucleotide adenylyltransferase immobilization: take nicotinamide-nucleotide adenylyltransferase thick leach protein or part pure
The albumen of change is diluted to protein content 5- with enzyme buffer liquid (0.02MTris HCl/0.001M EDTA, pH7.0 solution) is washed
10mg/ml.Enzyme dilution and PB solution (2.0mol/L potassium dihydrogen phosphate, pH7.5) are mixed in equal volume, epoxy type is added and fixes
Change zymophore LX 3000 (10 milligrams of enzymes/gram carrier), is reacted 20 hours for 25 DEG C in shaking table (revolving speed 100rpm).Reaction is completed
Sock filtration is used afterwards, is cleaned 5-6 times with enzyme buffer liquid is washed, is obtained immobilization nicotinamide-nucleotide adenylyltransferase.
Nicotinamide adenine dinucleotide is prepared with immobilization nicotinamide-nucleotide adenylyltransferase: preparing substrate solution:
The trinosin (ATP) of nicotinamide nucleotide, 10mM containing 5mM, 100mMTris hydrochloride buffer and final concentration of
The MgCl of 10mM2, adjust pH to 7.5.1 milliliter of substrate solution is taken, 0.05 gram of immobilization nicotinamide riboside adenylyl is then added and turns
Enzyme is moved, reaction 2-20 hours is carried out in 37 DEG C.Centrifugation (10 DEG C, 17800g, 15 minutes) simultaneously collects supernatant.Pass through high pressure liquid phase
The content of nicotinamide adenine dinucleotide in chromatography (HPLC) measurement gained supernatant.The result shows that nicotinamide nucleotide turns
The conversion ratio for turning to nicotinamide adenine dinucleotide is more than 80%.
Blood-fat reducing composition described in the present embodiment can be applied in blood lipid-lowering medicine or health food.
Embodiment 2
The present embodiment provides a kind of blood-fat reducing compositions comprising major ingredient and auxiliary material, wherein major ingredient in parts by weight, including
10 parts of NADH, 8 parts of Herba Epimedii, 8 parts of ginsenoside PPD, 6 parts of ginseng saponin Rh 2s, 5 parts of grape seed extracts, 5 parts of chondroitin sulfates
Element, 6 parts of ursodesoxycholic acid, 4 parts of Sialic acids, 7 parts of s- Ademetionines, 8 parts of γ-aminobutyric acids, 10 parts of balsam pear seed extracts.
In parts by weight, the auxiliary material includes 5 parts of Radix Rehmanniae, purple 3 parts of pone, 4 parts of cassia seed, 4 parts of radix aconiti agrestis snake, Rhizoma Chuanxiong 3
Part, 2 parts of pheretima, 3 parts of hoveniae semoveniae semen, 6 parts of schizonepeta carbon, aobvious 4 parts of arteries and veins Inula britannica chinensis, 2 parts of great burdock achene, 1 part of olibanum, 1 part of fleabane flower, dried orange peel
0.5 part, 2 parts of Nipagin complex esters, 2 parts of fumaric acid, 3 parts of xylitol, 6 parts of microcrystalline cellulose, sorbitan fatty acid ester 1
Part, 1 part of magnesium stearate, 2 parts of croscarmellose sodium, 2 parts of magnesium hydroxide.
The present embodiment also provides a kind of blood fat reducing preparation, and the blood fat reducing preparation includes above-mentioned composition, the reducing blood lipid
Preparation is prepared via a method which:
S1, major ingredient and auxiliary material are crossed into 80 meshes respectively, keep grain graininess uniform；
S2, proportionally major ingredient, auxiliary material and water stirred at 40 DEG C；
S3,1h is stirred after the obtained mixture of step S2 is warming up to 50 DEG C to get the aqua of reduction blood lipid is promoted.
Blood-fat reducing composition described in the present embodiment can be applied in blood lipid-lowering medicine or health food.
Embodiment 3
The present embodiment provides a kind of blood-fat reducing compositions comprising major ingredient and auxiliary material, wherein major ingredient in parts by weight, including
8 parts of NADH, 4 parts of Herba Epimedii, 6 parts of ginsenoside PPD, 3 parts of ginseng saponin Rh 2s, 4 parts of grape seed extracts, 3 parts of chondroitin sulfates
Element, 4 parts of ursodesoxycholic acid, 2 parts of Sialic acids, 4 parts of s- Ademetionines, 5 parts of γ-aminobutyric acids, 3 parts of balsam pear seed extracts.
In parts by weight, the auxiliary material includes aobvious 6 parts of arteries and veins Inula britannica chinensis, 4 parts of great burdock achene, 3 parts of olibanum, 2 parts of fleabane flower, dried orange peel
3 parts, 2 parts of milk thistle, 2 parts of amaranth of thorn, 1 part of semen astragali complanati, 0.5 part of mulberries, 3 parts of turmeric, 5 parts of sorbitan fatty acid ester, tristearin
3 parts of sour magnesium, 6 parts of croscarmellose sodium, 5 parts of magnesium hydroxide, pregelatinated form sediment 1 part, 1 part of calcium sulfate.
The present embodiment also provides a kind of blood fat reducing preparation, and the blood fat reducing preparation includes above-mentioned composition, the reducing blood lipid
Preparation is prepared via a method which:
S1, major ingredient and auxiliary material are crossed into 50 meshes respectively, keep grain graininess uniform；
S2, proportionally major ingredient, auxiliary material and water stirred at 30 DEG C；
S3,1h is stirred after the obtained mixture of step S2 is warming up to 50 DEG C to get the aqua of reduction blood lipid is promoted.
Blood-fat reducing composition described in the present embodiment can be applied in blood lipid-lowering medicine or health food.
Embodiment 4
The present embodiment provides a kind of blood-fat reducing compositions comprising major ingredient and auxiliary material, wherein major ingredient in parts by weight, including
6 parts of NADH, 5 parts of Herba Epimedii, 5 parts of ginsenoside PPD, 4 parts of ginseng saponin Rh 2s, 3 parts of grape seed extracts, 4 parts of chondroitin sulfates
Element, 3 parts of ursodesoxycholic acid, 3 parts of Sialic acids, 5 parts of s- Ademetionines, 6 parts of γ-aminobutyric acids, 7 parts of balsam pear seed extracts.
In parts by weight, the auxiliary material includes 3 parts of Radix Rehmanniae, purple 2 parts of pone, 3 parts of cassia seed, 3 parts of radix aconiti agrestis snake, Rhizoma Chuanxiong 2
Part, 1 part of pheretima, 1.5 parts of hoveniae semoveniae semen, 4 parts of schizonepeta carbon, aobvious 5 parts of arteries and veins Inula britannica chinensis, 3 parts of great burdock achene, 2 parts of olibanum, 1.5 parts of fleabane flower,
1.5 parts of dried orange peel, 6 parts of milk thistle, thorn 4 parts of amaranth, 3 parts of semen astragali complanati, 3 parts of mulberries, 5 parts of turmeric, pregelatinated form sediment 10 parts, 5 parts of calcium sulfate,
3 parts of fumed silica, 1 part of lactose.
The present embodiment also provides a kind of blood fat reducing preparation, and the blood fat reducing preparation includes above-mentioned composition, the reducing blood lipid
Preparation is prepared via a method which:
S1, dry major ingredient and auxiliary material each component are crossed into 60 meshes, and weighing mixing in proportion；
Whole grain and compressing tablet process are carried out after S2, the mixture drying for obtaining step S1, is promoted the piece for reducing blood lipid
Agent.
Blood-fat reducing composition described in the present embodiment can be applied in blood lipid-lowering medicine or health food.
Embodiment 5
The present embodiment provides a kind of blood-fat reducing compositions comprising major ingredient and auxiliary material, wherein major ingredient in parts by weight, including
9 parts of NADH, 4 parts of Herba Epimedii, 3 parts of ginsenoside PPD, 3.5 parts of ginseng saponin Rh 2s, 2.5 parts of grape seed extracts, 2 parts of sulfuric acid are soft
Ossein, 2.5 parts of ursodesoxycholic acid, 2.5 parts of Sialic acids, 3 parts of s- Ademetionines, 4.5 parts of γ-aminobutyric acids, 5 parts of balsampear seeds mention
Take object.
In parts by weight, the auxiliary material includes 2 parts of hoveniae semoveniae semen, 3 parts of schizonepeta carbon, aobvious 4.5 parts of arteries and veins Inula britannica chinensis, great burdock achene 2.5
Part, 1.5 parts of olibanum, 1.3 parts of fleabane flower, 2 parts of dried orange peel, 4 parts of milk thistle, thorn 3 parts of amaranth, 2 parts of semen astragali complanati, 2 parts of mulberries, 4 parts of turmeric,
It is 1 part of Nipagin complex esters, 1.5 parts of fumaric acid, 2 parts of xylitol, 4 parts of microcrystalline cellulose, 3 parts of sorbitan fatty acid ester, hard
2 parts of fatty acid magnesium.
The present embodiment also provides a kind of blood fat reducing preparation, and the blood fat reducing preparation includes above-mentioned composition, the reducing blood lipid
Preparation is prepared via a method which:
S1, major ingredient and auxiliary material each component are crossed into 60 meshes, and weighing mixing in proportion；
S2, the obtained mixture of step S1 is filled in flexible glue utricule, and passes through pelleting, sizing drying, washes ball, dries in the air
Ball picks up the step of ball, is promoted the soft capsule for reducing blood lipid.The flexible glue utricule is prepared by following steps: first will be sweet
Oil and water are added in glue pot, and gelatin and relevant auxiliary materials are then added, stir and vacuum outgas to get.
Blood-fat reducing composition described in the present embodiment can be applied in blood lipid-lowering medicine or health food.
Embodiment 6
The present embodiment provides a kind of blood-fat reducing compositions comprising major ingredient and auxiliary material, wherein major ingredient in parts by weight, including
8.4 parts of NADH, 3 parts of Herba Epimedii, 4.5 parts of ginsenoside PPD, 2 parts of ginseng saponin Rh 2s, 4.5 parts of grape seed extracts, 3.2 parts of sulphur
Aching and limp ossein, 4.5 parts of ursodesoxycholic acid, 2.8 parts of Sialic acids, 4.5 parts of s- Ademetionines, 5.3 parts of γ-aminobutyric acids, 6.5 parts
Balsam pear seed extract.
In parts by weight, the auxiliary material include 3.5 parts of Radix Rehmanniae, purple 2.8 parts of pone, 2.5 parts of cassia seed, 2 parts of radix aconiti agrestis snake,
1.8 parts of Rhizoma Chuanxiong, 1.5 parts of pheretima, 2.5 parts of hoveniae semoveniae semen, 3.2 parts of schizonepeta carbon, aobvious 4.5 parts of arteries and veins Inula britannica chinensis, 2.5 parts of great burdock achene, olibanum
2.5 parts, 1.8 parts of fleabane flower, 2.2 parts of dried orange peel, 4.5 parts of milk thistle, thorn 2.8 parts of amaranth, 1.5 parts of semen astragali complanati, 2.1 parts of mulberries, turmeric
3.5 parts, 1.5 parts of Nipagin complex esters, 1.2 parts of fumaric acid, 1.5 parts of xylitol, 4.5 parts of microcrystalline cellulose, Sorbitan alcohol ester
3.5 parts of fat acid esters, 1.8 parts of magnesium stearate, 3.5 parts of croscarmellose sodium, 4 parts of magnesium hydroxide, pregelatinated shallow lake 7 parts, sulphur
3.5 parts of sour calcium, 4.5 parts of fumed silica, 2.5 parts of lactose.
The present embodiment also provides a kind of blood fat reducing preparation, and the blood fat reducing preparation includes above-mentioned composition, the reducing blood lipid
Preparation is prepared via a method which:
S1, auxiliary material component is crushed as particle, the ethyl alcohol that volumetric concentration is 70% is added into particle and is heated to reflux mentions
2h is taken, the additive amount of ethyl alcohol is 5 times of component particles quality, and first time filtration treatment obtains the dregs of a decoction and medical fluid, by the dregs of a decoction and 3
The ethyl alcohol heating and refluxing extraction 1h of amount again, second of filtration treatment, the medical fluid that will be obtained by filtration for the first time, for the second time mix, and
It is spare that the thick paste that obtained relative density is 1.35-1.4 is concentrated under reduced pressure；
S2, the water that the obtained thick paste of step S1 is added to 7 times of amounts, heating and refluxing extraction 4h obtain volatile oil, the dregs of a decoction and medical fluid
Mixture, point take the volatile oil, and the dregs of a decoction and medical filtration are separated, obtain supernatant and the solid dregs of a decoction；
S3, major ingredient is mixed with the obtained volatile oil of step S2 and the dregs of a decoction, adds the water boiling and extraction 2h of 18 times of amounts, filters
To filtrate and filter residue, filtrate is centrifugated, obtains the first supernatant；By filter residue plus 12 times of water boiling and extraction 1h measured, filtering
Filtrate and filter residue are obtained, filtrate is centrifugated, obtains the second supernatant；By the first supernatant, the second supernatant and step S2
In supernatant mixing, be concentrated under reduced pressure be made relative density be 1.35-1.4 thick paste it is spare；
S4, dextrin, superfine silica gel powder are mixed and is stirred together for uniformly with thick paste made from step S3, the mixture that will be obtained
After drying and crushing, dextrin is added, is sieved, mixes and is packed into capsule shells after spraying into the volatile oil that step S2 is obtained, be promoted
Reduce the capsule of blood lipid.
Blood-fat reducing composition described in the present embodiment can be applied in blood lipid-lowering medicine or health food.
Experimental example
The reagents and materials used in the present invention are commercially available or can prepare by literature method.Tool is not specified in following experiments example
The experimental method of concrete conditions in the establishment of a specific crime, usually according to normal condition, or according to the normal condition proposed by manufacturer.
1, hypolipemic function is tested
Key instrument and reagent:
Key instrument: animal balance, disscting instrument, OLYMPUSAU400 automatic clinical chemistry analyzer, LD5-10B centrifugation
Machine.
Main agents: cholesterol (TC) kit, triglycerides (TG) kit, high-density lipoprotein cholesterol (HDL-
C) kit.
Experimental method: experimental animal cleaning grade SD kind male rat 48 are selected, constitution weight is 180-210g, safe by remittance intelligence
Health biotechnology (Beijing) Co., Ltd provides, credit number: SYXK (capital) 2014-0022.Divide cage to decontrol to raise, room temperature 22~
24 DEG C, relative humidity 52-58%, noise < 60 decibels, light and shade alt time 10/14 hour round the clock.
Metering grouping and given the test agent give time experiment and set three dosage groups, one control group high in fat, what dosage group used
Sample is prepared according to method in embodiment 5, and human body recommended amounts are everyone (adult) daily 8g.Tested material is divided into three dosage levels:
High dose is 2.67g/kgd, middle dosage 1.33g/kgd, low dosage 0.67g/kgd, is respectively equivalent to human body and pushes away
20 times, 10 times, 5 times of dosage are recommended, solvent is distilled water, and control group high in fat gives equal amount of distilled water.
High lipid food is formulated high lipid food: basal feed 78.8%, lard 10%, yolk powder 10%, cholesterol 1%, gallbladder
Salt 0.2%.Basal feed and high lipid food are provided by the feed corporation,Ltd that pulls together of Beijing Austria of section.
After lipid-lowering test is observed 1 week with basal feed feeding rat, fasting 16h takes tail blood, with OLYMPUS AU400
Automatic clinical chemistry analyzer measures serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C),
TG is taken into account according to TC level, animal is randomly divided into 4 groups: control group high in fat and three dosage groups.Since formal test, each group
Animal uses high lipid food instead, at the same tested material group by above-mentioned metering design stomach-filling give various concentration by test solution, control high in fat
Isometric distilled water is given in group stomach-filling, daily stomach-filling 1 time, continuous 30d, weighs weekly 1 time.Fasting 16h after experiment,
Pull out eyeball blood sampling measurement serum TC, TG, HDL-C.
Experimental result
Influence of the blood fat reducing preparation of the present invention to rat fat is as shown in table 1:
Table 1
| Group | TC | HDL-C | TG |
| High dose group | 1.95±0.12** | 1.64±0.12** | 1.13±0.11** |
| Middle dose group | 2.05±0.13** | 1.60±0.13** | 1.22±0.15** |
| Low dose group | 2.13±0.15** | 1.45±0.15* | 1.25±0.19* |
| Control group high in fat | 3.21±0.20** | 1.21±0.16 | 1.58±0.12 |
Compared with high in fat group, * P < 0.05,0.01 difference of * * P < have highly significant.
Seen from table 1, by test product each dosage group animal blood serum TC, TG, HDL-C, difference have conspicuousness ((P < 0.01, P <
0.05), blood fat reducing preparation of the present invention has the effect of significant reducing blood lipid.
Above-mentioned test proves that composition of the present invention has the function of lowering blood pressure and blood fat, treatment hypertension,
Significant in efficacy when the cardiovascular and cerebrovascular diseases such as hyperlipidemia, can be used for preparing has lowering blood pressure and blood fat and the prevention and treatment heart
In the drug of cranial vascular disease, food or health care product.
2, clinical trial
Typical case:
(1) Mr. Zhang, male, 50 years old, all day was out of strength, and taste are uncomfortable, slept bad, body is often tired, detects total gallbladder
Sterol value is 6.98, and as hyperlipidemia takes composition of the present invention after one month, symptom is good using the present embodiment as staple food
Turn, continues to take composition of the present invention after 3 months, blood lipid is restored to normal level.
(2) Mrs Zhao, female 45 years old, detect that total cholesterol value is 7.11, and hyperlipidemia, easy catching a cold, frequent stomach is glutted,
Vexed, mood is sensitive.With composite medicine, based on composition of the present invention, composition of the present invention is taken after one month, disease
Shape improves, and continues after taking 3 months, blood lipid is restored to normal level.
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And it is extended from this it is obvious variation or
It changes still within the protection scope of the invention.
Claims (10)
1. a kind of blood-fat reducing composition, which is characterized in that including major ingredient and auxiliary material, the major ingredient in parts by weight, including 2-10
Part NADH, 1-8 parts of Herba Epimedii, PPD, 1-6 parts of ginseng saponin Rh 2s of 2-8 parts of ginsenosides, 2-5 parts of grape seed extracts, 1-5 parts
Chondroitin sulfate, 1-6 part ursodesoxycholic acid, 1-4 parts of Sialic acids, 1-7 parts of s- Ademetionines, 1-8 parts of γ-aminobutyric acids, 1-
10 parts of balsam pear seed extracts.
2. blood-fat reducing composition according to claim 1, which is characterized in that the auxiliary material is in parts by weight, including as follows
Component it is at least eight kinds of: 2-5 parts of Radix Rehmanniae, purple 1-3 parts of pone, 2-4 parts of cassia seed, 1-4 parts of radix aconiti agrestis snake, 1-3 parts of Rhizoma Chuanxiong, pheretima
0.5-2 parts, 0.3-3 parts of hoveniae semoveniae semen, 2-6 parts of schizonepeta carbon, aobvious 4-6 parts of arteries and veins Inula britannica chinensis, 2-4 parts of great burdock achene, 1-3 parts of olibanum, oil lamp
1-2 parts of flower, 0.5-3 parts of dried orange peel, 2-6 parts of milk thistle, thorn amaranth 2-4 parts, 1-3 parts of semen astragali complanati, 0.5-3 parts of mulberries, 3-5 parts of turmeric.
3. blood-fat reducing composition according to claim 2, which is characterized in that the auxiliary material in parts by weight, further include as
At least three kinds of lower component: 0.5-2 parts of Nipagin complex esters, 1-2 parts of fumaric acid, 1-3 parts of xylitol, 3-6 parts of microcrystalline cellulose,
1-5 parts of sorbitan fatty acid ester, 1-3 parts of magnesium stearate, 2-6 parts of croscarmellose sodium, 2-5 parts of magnesium hydroxide,
1-10 parts of pregelatinated shallow lake, 1-5 parts of calcium sulfate, 3-6 parts of fumed silica, 1-4 parts of lactose.
4. a kind of blood fat reducing preparation, which is characterized in that the preparation includes composition as described in any one of claims 1-3.
5. a kind of method for preparing preparation as claimed in claim 4, which comprises the steps of:
S1, major ingredient and auxiliary material are crossed into 30-80 mesh respectively, keep grain graininess uniform；
S2, proportionally major ingredient, auxiliary material and water stirred at 25-40 DEG C；
S3,1h is stirred to get reducing blood lipid aqua after the obtained mixture of step S2 is warming up to 50 DEG C.
6. a kind of method for preparing preparation as claimed in claim 4, which comprises the steps of:
S1, dry major ingredient and auxiliary material each component are crossed into 60 meshes, and weighing mixing in proportion；
Whole grain and compressing tablet process are carried out after S2, the mixture drying for obtaining step S1, obtains reducing blood lipid tablet.
7. a kind of method for preparing preparation as claimed in claim 4, which comprises the steps of:
S1, major ingredient and auxiliary material each component are crossed into 60 meshes, and weighing mixing in proportion；
S2, the obtained mixture of step S1 is filled in flexible glue utricule, and passes through pelleting, sizing drying, washes ball, the ball that dries in the air, picks up
The step of ball, is reduced blood lipid soft capsule.
8. a kind of method for preparing preparation as claimed in claim 4, which comprises the steps of:
S1, auxiliary material component is crushed as particle, addition ethyl alcohol and heating and refluxing extraction 2h into particle, the additive amount of ethyl alcohol is group
5 times for dividing granular mass, first time filtration treatment obtains the dregs of a decoction and medical fluid, by the dregs of a decoction and 3 times of ethyl alcohol heating and refluxing extractions measured
1h, second of filtration treatment mix the medical fluid being obtained by filtration for the first time, for the second time, and obtained relative density is concentrated under reduced pressure and is
The thick paste of 1.35-1.4 is spare；
S2, the water that the obtained thick paste of step S1 is added to 7 times of amounts, heating and refluxing extraction 4h obtain the mixed of volatile oil, the dregs of a decoction and medical fluid
Object is closed, divides and takes the volatile oil, and the dregs of a decoction and medical filtration are separated, obtains supernatant and the solid dregs of a decoction；
S3, major ingredient is mixed with the obtained volatile oil of step S2 and the dregs of a decoction, adds the water boiling and extraction 2h of 18 times of amounts, filter is obtained by filtration
Liquid and filter residue, filtrate is centrifugated, and obtains the first supernatant；By filter residue plus 12 times of water boiling and extraction 1h measured, it is obtained by filtration
Filtrate and filter residue, filtrate is centrifugated, and obtains the second supernatant；It will be in the first supernatant, the second supernatant and step S2
It is spare that the thick paste that obtained relative density is 1.35-1.4 is concentrated under reduced pressure in supernatant mixing；
S4, dextrin, superfine silica gel powder are mixed and are stirred together for uniformly with thick paste made from step S3, obtained mixture is dry
And after crushing, dextrin is added, is sieved, mixes and is packed into capsule shells after spraying into the volatile oil that step S2 is obtained, obtain reducing blood lipid glue
Capsule.
9. preparation method according to claim 8, which is characterized in that the volumetric concentration of the ethyl alcohol is 70%.
10. a kind of application of composition as described in any one of claims 1-3 in blood lipid-lowering medicine or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811159872.7A CN109200243A (en) | 2018-09-30 | 2018-09-30 | A kind of blood-fat reducing composition, preparation and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811159872.7A CN109200243A (en) | 2018-09-30 | 2018-09-30 | A kind of blood-fat reducing composition, preparation and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200243A true CN109200243A (en) | 2019-01-15 |
Family
ID=64982623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811159872.7A Withdrawn CN109200243A (en) | 2018-09-30 | 2018-09-30 | A kind of blood-fat reducing composition, preparation and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200243A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762367A (en) * | 2004-10-18 | 2006-04-26 | 孙民富 | Ursodeoxycholic acid pills formula and its preparation method |
| CN101199689A (en) * | 2007-12-24 | 2008-06-18 | 浙江省中药研究所有限公司 | Grape chrysanthemum capsule and preparing method thereof |
| CN101250237A (en) * | 2008-03-31 | 2008-08-27 | 浙江工业大学 | Non-solvent ectraction method of chondroitin sulfate |
| CN101264121A (en) * | 2008-04-30 | 2008-09-17 | 刘建辉 | Blood fat reducing health products and preparation |
| CN101875891A (en) * | 2010-06-08 | 2010-11-03 | 黑龙江大荒春酒业有限公司 | Preparation method of potable spirit rich in gamma-aminobutyric acid |
| CN107158334A (en) * | 2017-07-19 | 2017-09-15 | 贵州黔香园油脂有限公司 | A kind of tea oil oral liquid with healthcare function |
-
2018
- 2018-09-30 CN CN201811159872.7A patent/CN109200243A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762367A (en) * | 2004-10-18 | 2006-04-26 | 孙民富 | Ursodeoxycholic acid pills formula and its preparation method |
| CN101199689A (en) * | 2007-12-24 | 2008-06-18 | 浙江省中药研究所有限公司 | Grape chrysanthemum capsule and preparing method thereof |
| CN101250237A (en) * | 2008-03-31 | 2008-08-27 | 浙江工业大学 | Non-solvent ectraction method of chondroitin sulfate |
| CN101264121A (en) * | 2008-04-30 | 2008-09-17 | 刘建辉 | Blood fat reducing health products and preparation |
| CN101875891A (en) * | 2010-06-08 | 2010-11-03 | 黑龙江大荒春酒业有限公司 | Preparation method of potable spirit rich in gamma-aminobutyric acid |
| CN107158334A (en) * | 2017-07-19 | 2017-09-15 | 贵州黔香园油脂有限公司 | A kind of tea oil oral liquid with healthcare function |
Non-Patent Citations (2)
| Title |
|---|
| 季新明: "腺苷蛋氨酸用于治疗脂肪肝58例临床分析", 《第四军医大学学报》 * |
| 许立拔: "燕窝酸抗阿尔茨海默症作用及机制研究", 《广西医科大学硕士学位论文》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oakenfull et al. | Saponins | |
| CN101641111B (en) | Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity | |
| Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
| WO2015172608A1 (en) | Capsule for assisting in reducing blood fat and preparation method therefor | |
| JPH05286865A (en) | Production of pharmaceutical composition for selectively lowering level of lipid in blood | |
| CN102349941A (en) | Traditional Chinese medicine composition for relieving fatigue and improving anoxia endurance and preparation method thereof | |
| CN102600227A (en) | Compound functional red rice capsule | |
| CN108392519A (en) | A kind of hypoglycemic composition and its preparation and application | |
| CN109939143A (en) | A kind of Chinese medicine composition and preparation method thereof for hypoglycemic control complication | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN102114170B (en) | Traditional Chinese medicine composition for preventing and treating myocardial ischemia reperfusion injury and preparation method thereof | |
| CN109224029A (en) | Blood-fat reducing composition, preparation containing NMN and the preparation method and application thereof | |
| CN102596214B (en) | Composition for alleviating fatty liver | |
| CN109200243A (en) | A kind of blood-fat reducing composition, preparation and the preparation method and application thereof | |
| CN113499366B (en) | Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof | |
| RU2409381C1 (en) | Pharmaceutical composition for blood sugar and fat control, its manufacturing and administration thereof | |
| CN101336705B (en) | Health food and its preparation method | |
| CN105456277B (en) | Application of the ganodenic acid acid activity position in preparing blood fat reducing health products and drug | |
| CN109699887B (en) | Peony seed oil soft capsule for reducing blood fat and preparation method thereof | |
| CN103735603B (en) | A kind of compound antihyperglycemic soft capsule and preparation method thereof | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof | |
| CN102599501B (en) | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver | |
| CN102499322A (en) | Novel health-care food or drug with function of improving memory | |
| CN105232676B (en) | A kind of Chinese medicine for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190115 |
|
| WW01 | Invention patent application withdrawn after publication |